JP2018537100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537100A5 JP2018537100A5 JP2018529050A JP2018529050A JP2018537100A5 JP 2018537100 A5 JP2018537100 A5 JP 2018537100A5 JP 2018529050 A JP2018529050 A JP 2018529050A JP 2018529050 A JP2018529050 A JP 2018529050A JP 2018537100 A5 JP2018537100 A5 JP 2018537100A5
- Authority
- JP
- Japan
- Prior art keywords
- target molecule
- level
- expression
- tnf therapy
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 16
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 15
- 101001055245 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1B Proteins 0.000 claims description 12
- 102100026227 Interferon-induced protein with tetratricopeptide repeats 1B Human genes 0.000 claims description 12
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims description 11
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 claims description 11
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 claims description 11
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims description 11
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 claims description 11
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 claims description 11
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims description 11
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims description 11
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 claims description 10
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 9
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims description 9
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 claims description 9
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 9
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims description 9
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 claims description 9
- 239000000090 biomarker Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102100040618 Eosinophil cationic protein Human genes 0.000 claims description 8
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 101000711744 Homo sapiens Non-secretory ribonuclease Proteins 0.000 claims description 6
- 102100034217 Non-secretory ribonuclease Human genes 0.000 claims description 6
- 102100030009 Azurocidin Human genes 0.000 claims description 5
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 5
- 102100025975 Cathepsin G Human genes 0.000 claims description 5
- 102100027367 Cysteine-rich secretory protein 3 Human genes 0.000 claims description 5
- 101001052004 Escherichia phage T5 L-shaped tail fiber protein pb1 Proteins 0.000 claims description 5
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 claims description 5
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 5
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 claims description 5
- 101000726258 Homo sapiens Cysteine-rich secretory protein 3 Proteins 0.000 claims description 5
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 claims description 5
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 5
- 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 claims description 5
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims description 5
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 5
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 5
- 102100036348 Neutrophil defensin 4 Human genes 0.000 claims description 5
- 102100033174 Neutrophil elastase Human genes 0.000 claims description 5
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 5
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 claims description 5
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 claims description 5
- 102100032241 Lactotransferrin Human genes 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 108010008165 Etanercept Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 241000208340 Araliaceae Species 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 229940090100 cimzia Drugs 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940073621 enbrel Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 210000003918 fraction a Anatomy 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 238000012165 high-throughput sequencing Methods 0.000 claims 1
- 229940048921 humira Drugs 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229940116176 remicade Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940068638 simponi Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 101710142533 Interferon-induced protein 44-like Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521357.2 | 2015-12-03 | ||
| GBGB1521357.2A GB201521357D0 (en) | 2015-12-03 | 2015-12-03 | Methods for predicting response to anti-TNF therapy |
| PCT/GB2016/053798 WO2017093750A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537100A JP2018537100A (ja) | 2018-12-20 |
| JP2018537100A5 true JP2018537100A5 (enExample) | 2020-01-16 |
Family
ID=55234362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529050A Pending JP2018537100A (ja) | 2015-12-03 | 2016-12-02 | 抗ｔｎｆ療法に対する応答を予測する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190367984A1 (enExample) |
| EP (1) | EP3384044A1 (enExample) |
| JP (1) | JP2018537100A (enExample) |
| CN (1) | CN108291261A (enExample) |
| AU (1) | AU2016364003A1 (enExample) |
| CA (1) | CA3005695A1 (enExample) |
| GB (1) | GB201521357D0 (enExample) |
| WO (1) | WO2017093750A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| WO2019018440A1 (en) * | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS |
| CN108047327B (zh) * | 2017-11-29 | 2020-08-07 | 中国医学科学院北京协和医院 | 一种检测骨关节炎的生物标志物及其应用 |
| US20200399698A1 (en) * | 2018-02-19 | 2020-12-24 | Genefron Ltd. | Methods of determining response to tnf alpha blockers |
| EP3765634A4 (en) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES |
| US20210104321A1 (en) * | 2018-11-15 | 2021-04-08 | Ampel Biosolutions, Llc | Machine learning disease prediction and treatment prioritization |
| GB2603294A (en) | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
| WO2021067667A1 (en) * | 2019-10-04 | 2021-04-08 | The Regents Of The University Of Michigan | Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis |
| KR20230165746A (ko) * | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| WO2022190036A2 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Methods for predicting treatment response in ulcerative colitis |
| CN113373218A (zh) * | 2021-08-04 | 2021-09-10 | 杭州浙大迪迅生物基因工程有限公司 | 一组检测人嗜酸性粒细胞阳离子蛋白mRNA表达的引物组和试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069533B1 (en) * | 2006-07-13 | 2012-11-07 | Life Technologies Corporation | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis |
| WO2008132176A2 (en) * | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| CA2690898A1 (en) * | 2007-06-08 | 2008-12-18 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| EP2192197A1 (en) * | 2008-11-27 | 2010-06-02 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist |
| MX353186B (es) * | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| US20130042333A1 (en) * | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
| US9809854B2 (en) * | 2012-11-15 | 2017-11-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
-
2015
- 2015-12-03 GB GBGB1521357.2A patent/GB201521357D0/en not_active Ceased
-
2016
- 2016-12-02 CA CA3005695A patent/CA3005695A1/en not_active Abandoned
- 2016-12-02 CN CN201680071029.6A patent/CN108291261A/zh active Pending
- 2016-12-02 AU AU2016364003A patent/AU2016364003A1/en not_active Abandoned
- 2016-12-02 US US15/780,762 patent/US20190367984A1/en not_active Abandoned
- 2016-12-02 WO PCT/GB2016/053798 patent/WO2017093750A1/en not_active Ceased
- 2016-12-02 JP JP2018529050A patent/JP2018537100A/ja active Pending
- 2016-12-02 EP EP16808777.3A patent/EP3384044A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537100A5 (enExample) | ||
| Yao et al. | Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus | |
| JP5675829B2 (ja) | 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法 | |
| Aldridge et al. | T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3+ Th2 phenotype | |
| Goronzy et al. | Prognostic markers of radiographic progression in early rheumatoid arthritis | |
| Mitsunaga et al. | Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2 | |
| Braga et al. | Influence of IL10 (rs1800896) polymorphism and TNF-α, IL-10, IL-17A, and IL-17F serum levels in ankylosing spondylitis | |
| CA2889087C (en) | Diagnostic method for predicting response to tnf.alpha. inhibitor | |
| Xu et al. | Association between IL17A and IL17F polymorphisms and risk of Henoch–Schonlein purpura in Chinese children | |
| WO2014135546A1 (en) | Methods and compositions for the diagnosis of alzheimer's disease | |
| EP2635966A1 (en) | Biomarkers for predicting progressive joint damage | |
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| CA3005695A1 (en) | Methods for predicting response to anti-tnf therapy | |
| WO2010118210A1 (en) | Methods of predicting complication and surgery in crohn's disease | |
| Andreu-Sánchez et al. | Phage display sequencing reveals that genetic, environmental, and intrinsic factors influence variation of human antibody epitope repertoire | |
| CN113196059B (zh) | 表征疾病活动性的系统性红斑狼疮(sle)疾病活动性免疫指数的生物标志物 | |
| Fattah et al. | The expression of zinc finger 804a (ZNF804a) and cyclin-dependent kinase 1 (CDK1) genes is related to the pathogenesis of rheumatoid arthritis | |
| Walczak et al. | Long-range PCR libraries and next-generation sequencing for pharmacogenetic studies of patients treated with anti-TNF drugs | |
| Wang et al. | Association of interleukin-8 gene polymorphisms with the risk of hepatocellular carcinoma | |
| US8580528B2 (en) | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy | |
| Surmiak et al. | Expression profile of proinflammatory genes in neutrophil-enriched granulocytes stimulated with native anti-PR3 autoantibodies | |
| Guzel et al. | Next generation sequencing based multiplex long-range PCR for routine genotyping of autoinflammatory disorders | |
| KR102155306B1 (ko) | 고밀도지질단백질콜레스테롤 수준을 예측하기 위한 조성물, 키트, 및 이를 이용한 방법 | |
| Somers et al. | Optimization of high‐throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis | |
| Al-Garawi et al. | Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights |